Pan Tumor Rollover Study
A phase 2 trial of Nivolumab, Ipilimumab, Cabozantinib, Trametinib, Capecitabine and Bevacizumab in advanced solid tumours, run by Bristol-Myers Squibb, now recruiting.
Overview
Pan Tumor Rollover Study is a phase 2 interventional study registered as NCT03899155 by Bristol-Myers Squibb, with 1500 participants planned, started 2019-08-09 and due to reach its primary completion in 2029-08-25. Interventions recorded: Nivolumab, Ipilimumab, Cabozantinib, Trametinib, Relatlimab and Nivolumab + Relatlimab.
Similar pages
not linked directly; found by shared links- TrialA Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Shares Bevacizumab, Bristol Myers Squibb, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
Shares Advanced Accelerator Applications (Novartis), Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
Shares Ipilimumab, Bristol Myers Squibb, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
Shares Ipilimumab, Bevacizumab, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
Shares Bevacizumab, Bristol Myers Squibb, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
Shares Bristol Myers Squibb, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Shares Ipilimumab, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialExtension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Shares Cabozantinib, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.